1. Clinical Overview
Homatropine Hydrobromide is a semisynthetic, intermediate-acting, antimuscarinic, anticholinergic agent used primarily as a mydriatic and cycloplegic for ophthalmic diagnostic procedures. It is a tropane alkaloid derived from atropine, with a shorter duration of action. In the 2% w/v concentration, it is formulated as an ophthalmic solution for topical instillation into the conjunctival sac.
| Onset | Duration | Bioavailability |
|---|---|---|
| Mydriasis: 15-30 minutes. Cycloplegia: 30-60 minutes. | Mydriasis: 6-24 hours. Cycloplegia: 10-48 hours. | Negligible systemic absorption following proper topical ophthalmic administration. However, absorption via the nasolacrimal duct can occur. |
2. Mechanism of Action
Homatropine competitively blocks the action of acetylcholine at postganglionic muscarinic receptors in the sphincter muscle of the iris and the ciliary muscle of the eye. This blockade inhibits parasympathetic (cholinergic) tone.
3. Indications & Uses
- Refraction (Cycloplegic refraction)
- Fundus Examination (Ophthalmoscopy)
- Treatment of Uveitis (Posterior synechiae prevention)
4. Dosage & Administration
Adult Dosage: For refraction: 1-2 drops of 2% solution in the eye(s), repeated every 10-15 minutes for 3-5 doses as needed. For uveitis: 1-2 drops up to every 3-4 hours.
Administration: Wash hands. Tilt head back. Gently pull lower eyelid down to form a pouch. Instill prescribed number of drops. Close eyes gently and apply pressure to the lacrimal sac (inner corner of eye) for 1-2 minutes to minimize systemic absorption. Do not touch dropper tip to any surface. Wait at least 5 minutes before instilling any other ophthalmic medication.
5. Side Effects
Common side effects may include:
- Transient stinging/burning on instillation
- Blurred vision (loss of accommodation)
- Photophobia
- Increased intraocular pressure (in susceptible individuals)
- Conjunctival hyperemia (redness)
6. Drug Interactions
| Drug | Effect | Severity |
|---|---|---|
| Other Anticholinergics (e.g., Atropine, Ipratropium, Oxybutynin, TCAs) | Additive systemic anticholinergic side effects (dry mouth, blurred vision, constipation, urinary retention, tachycardia, confusion). | Major |
| Potassium Chloride (wax-matrix tablets) | Increased risk of GI lesions due to reduced GI motility. | Moderate |
| Digoxin | Increased serum digoxin levels due to reduced GI motility, increasing risk of toxicity. | Moderate |
| Phenothiazines (e.g., Chlorpromazine) | Increased anticholinergic effects and potential for hyperthermia. | Moderate |
| Sympathomimetics (e.g., Phenylephrine eye drops) | Additive mydriatic effect. | Moderate |
7. Patient Counselling
- DO apply pressure on the inner corner of the eye (lacrimal sac) for 1-2 minutes after instillation.
- DO wash hands before and after use.
- DO NOT touch the dropper tip to your eye, fingers, or any surface.
- DO NOT wear soft contact lenses during treatment; the preservative (benzalkonium chloride) may be absorbed.
- DO inform your doctor if you are pregnant, planning pregnancy, or breastfeeding.
- DO inform your doctor about all other medicines you are taking.
8. Toxicology & Storage
Overdose: Topical overdose manifests as exaggerated pharmacological effects: severe blurred vision, photophobia, tachycardia, dry hot skin, dry mouth, thirst, difficulty swallowing, restlessness, confusion, hallucinations, delirium, hyperthermia, urinary retention, ileus, and respiratory depression.
Storage: Store at controlled room temperature (15°C to 25°C). Protect from light. Keep the bottle tightly closed when not in use. Do not freeze. Keep out of reach and sight of children. Discard the solution one month after opening the bottle (check manufacturer's instructions).